Deep Phenotyping of Pathology‐Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients
Clinical Genetics · 2025
DOI: 10.1111/cge.14759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Genetics, 2025. Verfasst von Ane J Schei-Andersen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: PTEN Phosphohydrolase, Hamartoma Syndrome, Multiple. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
PTEN Hamartoma Tumor Syndrome (PHTS) is a rare hereditary syndrome. PHTS has a variable phenotype characterized by benign lesions and increased cancer risks. Clarifying the extent of the benign phenotype could facilitate early recognition of PHTS patients before cancer development. Therefore, we assessed the spectrum, frequency, and age of excerpt of pathology‐confirmed benign lesions in PHTS patients. Pathology reports were collected for 379 patients with a pathogenic PTEN variant from the Dutch nationwide pathology databank (Palga). Benign lesions were classified as PHTS‐related based on current clinical diagnostic guidelines and non‐PHTS‐related lesions by ICD‐10 codes. Age of last follow‐up was year of pathology request minus birth year. Analyses were stratified by sex and index status. Patients presented mainly with gastrointestinal (54%), skin (47%), thyroid (31%) and vascular lesions (26%). Males developed lipomas at an early age (9 years (5–34)). Females developed endometrial hyperplasia (16%) at an earlier age (41 years (35–49)) and uterine polyps (13%) more often than the general population. No significant differences were observed between sexes or index and non‐index patients. The results are reflective of current diagnostic guidelines. Early‐onset lipomas may be useful for early detection of PHTS patients. Additionally, uterine polyps should be considered for inclusion as a PHTS‐related lesion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
- Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department of Pediatric Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.
ORCID-Profile: Ane J Schei-Andersen, Janneke H M Schuurs-Hoeijmakers, Rachel van der Post, Arjen R Mensenkamp, Jolanda Schieving, Janet R Vos, Nicoline Hoogerbrugge
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
Zitieren
APA
Schei-Andersen, A. J., Schuurs-Hoeijmakers, J. H. M., van der Post, R., Mensenkamp, A. R., Schieving, J., PTEN Study Group, Vos, J. R., & Hoogerbrugge, N. (2025). Deep Phenotyping of Pathology‐Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients. Clinical Genetics. https://doi.org/10.1111/cge.14759
Vancouver
Schei-Andersen AJ, Schuurs-Hoeijmakers JHM, van der Post R, Mensenkamp AR, Schieving J, PTEN Study Group, et al. Deep Phenotyping of Pathology‐Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients. Clinical Genetics. 2025. doi:10.1111/cge.14759
BibTeX
@article{ScheiAndersen2025,
author = {Schei-Andersen, Ane J and Schuurs-Hoeijmakers, Janneke H M and van der Post, Rachel and Mensenkamp, Arjen R and Schieving, Jolanda and PTEN Study Group, PTEN Study Group and Vos, Janet R and Hoogerbrugge, Nicoline},
title = {Deep Phenotyping of Pathology‐Confirmed Benign Lesions in PTEN Hamartoma Tumor Syndrome Patients},
journal = {Clinical Genetics},
year = {2025},
doi = {10.1111/cge.14759}
}
EUVIMED